Skip to main content
Premium Trial:

Request an Annual Quote

MDS Forms Committee to Review 'Alternatives'

NEW YORK (GenomeWeb News) – MDS today said that it has formed a committee of independent directors to support the firm's ongoing process of "reviewing alternatives to improve shareholder value."

The committee includes William Anderson, Robert Luba, James MacDonald, and Gregory Spivy, all of whom are independent of management of the company. In addition to the new committee, investment banks Goldman Sachs and RBC Capital Markets are assisting MDS as financial advisors.

The firm said that there is no assurance that the review will result in any specific strategic or financial transaction and no timetable has been set for its completion.

Last summer, MDS undertook a restructuring effort that included laying off 210 employees aimed at improving profitability in its MDS Pharma Services and MDS Analytical Technologies business units.

In December, MDS reported that its fourth-quarter revenues had declined 4 percent to $322 million. MDS Analytical Technologies, which houses the firm's mass spectrometry and Molecular Devices businesses, had a drop in revenue to $99 million from $108 million. The firm said that the division continues to be impacted by soft demand for high-end instruments.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.